Oramed Pharmaceuticals (ORMP) Stock Overview
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ORMP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oramed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$3.09 |
| 52 Week Low | US$1.82 |
| Beta | 1.62 |
| 1 Month Change | -1.30% |
| 3 Month Change | -2.98% |
| 1 Year Change | 3.17% |
| 3 Year Change | -50.54% |
| 5 Year Change | -38.87% |
| Change since IPO | 1,153.95% |
Recent News & Updates
Recent updates
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
May 31
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Shareholder Returns
| ORMP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.6% | 3.4% | 1.4% |
| 1Y | 3.2% | -9.6% | 11.6% |
Return vs Industry: ORMP exceeded the US Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: ORMP underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| ORMP volatility | |
|---|---|
| ORMP Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ORMP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ORMP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Nadav Kidron | www.oramed.com |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses.
Oramed Pharmaceuticals Inc. Fundamentals Summary
| ORMP fundamental statistics | |
|---|---|
| Market cap | US$92.32m |
| Earnings (TTM) | -US$28.24m |
| Revenue (TTM) | US$2.00m |
Is ORMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORMP income statement (TTM) | |
|---|---|
| Revenue | US$2.00m |
| Cost of Revenue | US$1.99m |
| Gross Profit | US$13.00k |
| Other Expenses | US$28.25m |
| Earnings | -US$28.24m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.65% |
| Net Profit Margin | -1,411.90% |
| Debt/Equity Ratio | 0% |
How did ORMP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 04:32 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oramed Pharmaceuticals Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Christopher James | FBR Capital Markets & Co. |